{"schema_version":"secwatch.filing_event.v1","accession":"0001127537-22-000009","form_type":"8-K/A","ticker":"LUNG","cik":"0001127537","company_name":"Pulmonx Corp","filed_at":"2022-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:04:05.489636+00:00","generated_at":"2026-06-27T04:02:23.436600+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Pulmonx Q4 revenue $13.7M (+39% YoY); FY2022 guidance $55M-$60M","bullets":["Q4 2021 revenue $13.7M, up 39% YoY; FY2021 revenue $48.4M, up 48% YoY.","Gross margin improved to 74.8% in Q4 and 73.6% for FY2021, vs 72.0% and 64.8% a year ago.","Net loss Q4 $13.0M ($0.35/sh); FY net loss $48.7M ($1.35/sh).","FY2022 revenue guidance $55M-$60M; Q1 2022 guidance $9M-$10M, reflecting COVID impact.","U.S. treatment centers for Zephyr Valves expanded to 214, up 45% from start of 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001127537-22-000009","json":"https://secwatch.observer/filing/0001127537-22-000009.json","markdown":"https://secwatch.observer/filing/0001127537-22-000009.md","text":"https://secwatch.observer/filing/0001127537-22-000009.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1127537/000112753722000009/0001127537-22-000009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1127537/000112753722000009/lung-20220223.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T04:02:23.436600+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}